Dezrinit spray, nasal 50mcg/dose 140 doses 18g 1pc

Composition

Active ingredient:  

mometasone furoate monohydrate (based on mometasone furoate) 0.052 mg (0.050 mg);

Auxiliary substances:  

avicel RC-591 (cellulose microcrystalline, carmellose sodium) 2 mg,

glycerol – 2.1 mg,

benzalkonium chloride solution of 500 g/l and 40 µg of

Polysorbate 80 – 10 mg,

citric acid monohydrate – 200 mcg,

sodium citrate dihydrate – 280 mcg,

water d/and – q. s. up to 100 mg.

Pharmacological action

Mometasone is a synthetic glucocorticosteroid (corticosteroid) for topical use. It has an anti-inflammatory and anti-allergic effect. The local anti-inflammatory effect of the drug is manifested when it is used in doses that do not cause systemic effects.

Inhibits the release of inflammatory mediators. Increases the production of lipomodulin, which is an inhibitor of phospholipase A, which causes a decrease in the release of arachidonic acid and, accordingly, inhibits the synthesis of arachidonic acid metabolism products – cyclic endoperoxides, prostaglandins.

It prevents the marginal accumulation of neutrophils, which reduces inflammatory exudate and lymphokine production, inhibits macrophage migration, and reduces the processes of infiltration and granulation.

Reduces inflammation by reducing the formation of chemotaxis substance (influence on late allergic reactions), inhibits the development of an immediate allergic reaction (by inhibiting the formation of arachidonic acid metabolites and reducing the release of inflammatory mediators from mast cells).

In studies with provocative tests with the application of antigens to the nasal mucosa, a high anti-inflammatory activity of the drug was demonstrated, both in the early and late stages of an allergic reaction.

When compared with placebo, there was a decrease in the level of histamine and eosinophil activity, as well as a decrease (compared to the initial one) in the number of eosinophils, neutrophils, and epithelial cell proteins.

Indications

For inhalation use: basic therapy of bronchial asthma of any severity; COPD.

For intranasal use: treatment of seasonal and perennial allergic rhinitis in adults, adolescents and children 2 years of age;

acute sinusitis or acute exacerbation of chronic sinusitis in adults (including the elderly) and adolescents from 12 years (as adjuvant therapeutic agent in the treatment with antibiotics);

acute rhinosinusitis with mild and moderately severe symptoms with no signs of serious bacterial infection in patients aged 12 years and older;

prophylaxis of seasonal allergic rhinitis moderate and severe in adults and adolescents from 12 years of age; nasal polyposis, accompanied by a violation of nasal breathing and sense of smell in adults.

Contraindications

Hypersensitivity to mometasone.

For inhalation use: children under 12 years of age.

For intranasal use: recent surgery or nasal trauma with damage to the nasal mucosa – before wound healing (due to the inhibitory effect of corticosteroids on healing processes); children and adolescents under 18 years of age with nasal polyposis; children under 12 years of age with acute sinusitis or exacerbation of chronic sinusitis; children under 2 years of age with seasonal and year-round allergic rhinitis.

Side effects

Burning, itching, irritation, dryness and atrophy of the nasal mucosa, nosebleeds, pharyngitis, candidiasis, bronchospasm, secondary infection.

How to take, course of use and dosage

The dosage regimen is set individually, depending on the indications, the patient’s age, the method of use, and the dosage form used.

Special instructions

It is not intended for use in ophthalmology. Adrenal function should be monitored regularly (so as not to miss the symptoms of hypercorticism). Newborns whose mothers used HA during pregnancy should be carefully examined for possible adrenal hypofunction.

If local infections of the nose or pharynx develop, mometasone is gradually discontinued. Treatment of children is carried out according to strict indications and under medical supervision, since the development of systemic side effects is possible.

Form of production

Nasal spray

Storage conditions

At a temperature of 2-25 °C. (do not freeze)

Shelf life

3 years

Active ingredient

Mometasone

Conditions of release from pharmacies

By prescription

Dosage form

nasal spray

Description

For adults as prescribed by a doctor, Children over 2 years of age, Children as prescribed by a doctor

Indications

Sinusitis, Allergic Rhinitis, Adenoids, Pollinosis